PET-FAPI imaging to find pancreatic cancer earlier
Official title: Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)
Run by Institut Curie · NCT06659705 · Data updated 2026-11-12
This will try a PET scan using a FAPI tracer to find early or returning pancreatic cancer in adults with recently diagnosed non‑metastatic PDAC who are enrolled in the HoMING cohort.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 35 (estimated) |
| Sponsor | Institut Curie Academic / other |
| Locations | 1 site (Saint-Cloud) |
| Status | Recruiting |
| Started | December 2, 2025 |
| Main results expected | August 4, 2029 |
| Study ends | August 8, 2030 |
| Registry record updated | April 15, 2026 |
| Trial ID | NCT06659705 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (>18) with cyto/histologically proven non‑metastatic PDAC (resectable, borderline or locally advanced) who are already enrolled in the HoMING prospective cohort and can undergo PET/CT imaging.
✕Probably not a fit
Patients with known metastatic disease at baseline, pregnant or breastfeeding women, legally protected adults without consent capacity, or individuals not enrolled in HoMING are not eligible and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional protocol uses repeated 68Ga-FAPI-46 PET/CT scans alongside standard 18F-FDG PET/CT and conventional imaging to develop and test imaging biomarkers in patients with newly diagnosed resectable, borderline, or locally advanced non‑metastatic PDAC. All participants must already be enrolled in the HoMING cohort and will receive a baseline FAPI and FDG PET/CT, additional pre-operative scans if they receive neoadjuvant therapy, and post-operative or post-treatment FAPI PET/CT starting about two months after surgery and then every three months. The co-primary goals are to detect occult metastatic disease at inclusion and to detect recurrence after resection with higher sensitivity than standard CT/MRI. Follow-up ends if conventional imaging documents progression or relapse, or at death, and FAPI findings will be compared with clinical, pathological and other imaging results from HoMING.
Why it matters
Potential benefit: If successful, FAPI PET could detect metastasis or recurrence earlier than standard scans, potentially allowing earlier treatment changes and better selection of patients for surgery.
How similar studies have gone: Early pilot studies and small series in PDAC and other cancers have shown promising tumor uptake and improved lesion detection with FAPI‑PET versus FDG‑PET, but large prospective validation is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Cyto/histologically proven PDAC 2. Non-metastatic proven PDAC on recent (\< 1 month) CT-scan and MRI 3. Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983) 4. Age \> 18 years old 5. Affiliation to a social security scheme 6. Signed informed consent Exclusion Criteria: 1. Protected adults (guardianship, curatorship or safeguarding justice) 2. Pregnant or breastfeeding woman 3. Women of childbearing potential not using one highly effective method of contraception
Where it's running
-
Institut Curie -site Saint-Cloud
Saint-Cloud, France Recruiting
Study contacts
- Principal investigator: Nicolas Deleval — Institut Curie
- Study coordinator: Marie-Emmanuelle LEGRIER
- Email: drci.promotion@curie.fr
- Phone: 0033156245765
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
KRAS Inhibitor ETX-929 in advanced solid tumors
This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.
-
Modified FOLFIRINOX with Pentamidine in Advanced Pancreatic Cancer
This study tests whether adding pentamidine to a modified FOLFIRINOX regimen helps people with advanced or metastatic pancreatic cancer.
-
Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502
This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.
-
Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer
This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.
-
Reach and Engagement of Genetic Education, Risk Assessment, and Testing Feasibility (GENET) for PDAC risk
This study tests whether online education plus a phone call from PanCAN helps Black, Latino/a, and Medicaid-enrolled people in Massachusetts learn about genetic and multi-cancer early detection testing and decide about getting tested.
-
Imaging study of 203Pb-RMX-VH-PIB in GBM and PDAC patients
This early-stage study tests a new imaging drug to see how it travels in the body and how much radiation different organs receive in adults with GBM or PDAC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.